<SEC-DOCUMENT>0001104659-20-129535.txt : 20201125
<SEC-HEADER>0001104659-20-129535.hdr.sgml : 20201125
<ACCEPTANCE-DATETIME>20201125163110
ACCESSION NUMBER:		0001104659-20-129535
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20201125
DATE AS OF CHANGE:		20201125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-250967
		FILM NUMBER:		201351050

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>tm2037003d2_s3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As Filed with the Securities and Exchange
Commission on November&nbsp;25, 2020</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5in; text-indent: 0.25in"><B>Registration
No.&nbsp;333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>UNDER</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ESSA PHARMA INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact name of Registrant as specified
in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><B>British Columbia</B></TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center"><B>47-2569713</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(State or other jurisdiction</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(I.R.S. Employer</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>of incorporation or organization)</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>Identification No.)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite&nbsp;720, 999 West Broadway</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vancouver, British Columbia V5Z 1K5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(778) 331-0962</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address and telephone number of registrants&rsquo;
principal executive offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CT Corporation System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>111 Eighth Avenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10011</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) 894-8940</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Name, address, including zip code,
and telephone number,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>including area code, of agent for service)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Copies to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ryan J. Dzierniejko,&nbsp;Esq.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Michael J. Hong,&nbsp;Esq.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Skadden, Arps, Slate, Meagher&nbsp;&amp;
        Flom LLP</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>222 Bay Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Toronto, Ontario M5K 1J5</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(416) 777-4700</B></P></TD>
    <TD STYLE="width: 34%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 33%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Joseph A. Garcia,&nbsp;Esq.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kyle Misewich,&nbsp;Esq.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Blake, Cassels&nbsp;&amp; Graydon LLP</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>595 Burrard Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vancouver, British Columbia V7X 1L3</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(604) 631-3300</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>From
time to time on or after the effective date of this Registration Statement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Approximate date of commencement of proposed
sale of the securities to the public)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the only securities being registered on this Form&nbsp;are
being offered pursuant to dividend or interest reinvestment plans, please check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on this Form&nbsp;are
to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, other than securities
offered only in connection with dividend or interest reinvestment plans, check the following box. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form&nbsp;is filed to register additional securities
for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form&nbsp;is a post-effective amendment filed pursuant
to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form&nbsp;is a registration statement pursuant to General
Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to
Rule&nbsp;462(e)&nbsp;under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form&nbsp;is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities
pursuant to Rule&nbsp;413(b)&nbsp;under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo; and &ldquo;emerging
growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 40%">Large&nbsp;accelerated&nbsp;filer</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 16%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 40%">Accelerated&nbsp;filer</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">Non-accelerated filer</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Smaller&nbsp;reporting&nbsp;company</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Emerging growth company</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&nbsp;7(a)(2)(b)&nbsp;of the Securities Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CALCULATION OF REGISTRATION FEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Title of Each Class&nbsp;of <BR>
Securities to be Registered</B></TD>
    <TD STYLE="white-space: nowrap; border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Amount to be<BR>
 Registered<SUP>(1)</SUP></B></TD>
    <TD STYLE="white-space: nowrap; border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Proposed&nbsp;&nbsp;Maximum<BR>
 Offering Price per<BR>
 Common Share</B></TD>
    <TD STYLE="white-space: nowrap; border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Proposed Maximum<BR>
 Aggregate Offering <BR>
Price</B></TD>
    <TD STYLE="white-space: nowrap; border-top: Black 1.5pt double; border-bottom: Black 1pt solid; vertical-align: bottom; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Amount of <BR>
Registration Fee</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt">Common Shares<SUP>(2)</SUP></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">7,370,000&nbsp;&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&ndash;<SUP>(3)</SUP></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&ndash;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&ndash;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Pursuant to Rule&nbsp;416(a)&nbsp;under the United States Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
this Registration Statement shall be deemed to cover any additional number of common shares of the registrant that may be issued
from time to time to prevent dilutions as a result of stock splits, stock dividends or similar transactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Comprised of 7,370,000 common shares issuable upon exercise of warrants issued to certain selling shareholders in connection
with a private placement completed by the registrant on August&nbsp;27, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Pursuant to Rule 415(a)(6) under the Securities Act, the Registrant is carrying forward to this registration statement a total
of 7,370,000 common shares issuable upon exercise of warrants that were previously registered on the Registrant's registration
statement on Form F-3 (File No. 333-234136) (the &quot;Prior Registration Statement&quot;). Pursuant to Rule 415(a)(6), the offering
of such unsold securities registered under the Prior Registration Statement will be deemed terminated as of the date of effectiveness
of this registration statement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Registrant hereby amends this Registration Statement
on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of
the Securities Act or until this Registration Statement shall become effective on such date as the Commission acting pursuant to
said Section&nbsp;8(a), may determine</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><B>The information in this preliminary prospectus
is not complete and may be changed. The selling shareholders may not sell these securities until the registration statement filed
with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>Subject to Completion, Dated
November&nbsp;25, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="tm2037003d2_s3img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ESSA PHARMA INC.</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>7,370,000 Common
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus covers 7,370,000 common shares of ESSA Pharma
Inc. that may be offered for resale by the selling shareholders identified in the &ldquo;Selling Shareholders&rdquo; section in
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No securities are being offered or sold by us pursuant to this
prospectus, and we will not receive any of the proceeds from the sale of the shares by the selling shareholders. We will not receive
any cash proceeds from the selling shareholders in connection with the exercise of the pre-funded warrants (the &ldquo;2019 Pre-Funded
Warrants) issued pursuant to the August&nbsp;27, 2019 public offering of equity securities of the Company in Canada and concurrent
private placement of equity securities in the United States (the &ldquo;August&nbsp;2019 Offering&rdquo;), which will be effected
on a &ldquo;net&rdquo; or &ldquo;cashless&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common shares are listed on the Nasdaq Capital Market (the
 &ldquo;Nasdaq&rdquo;) under the symbol &ldquo;EPIX.&rdquo; On November&nbsp;24, 2020, the closing price of our common shares
was US$6.50 on the Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling shareholders may, from time to time, sell, transfer
or otherwise dispose of any or all of their common shares directly to purchasers or through broker-dealers or agents. The common
shares may be sold in one or more transactions at fixed prices, prevailing market prices at the time of sale, prices related to
the prevailing market prices, varying prices determined at the time of sale or negotiated prices. See &ldquo;Plan of Distribution&rdquo;
beginning on page&nbsp;12 for more information about how the selling shareholders may sell or dispose of their shares. We
do not know when, in what amount, or the method by which the selling shareholders may offer the shares for sale. The selling shareholders
may sell any, all or none of the shares offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>An investment in our common shares involves a high degree
of risk. Before purchasing any common shares, you should consider carefully the risks described under &ldquo;Risk Factors&rdquo;
beginning on page&nbsp;1.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the U.S. Securities and Exchange Commission nor any
state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_001">THE COMPANY</A></TD>
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_001">1</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_002">RISK FACTORS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_002">1</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_003">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_003">2</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_004">EXCHANGE RATE INFORMATION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_004">7</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_005">USE OF PROCEEDS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_005">8</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_006">DIVIDEND POLICY</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_006">8</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_007">DESCRIPTION OF SHARE CAPITAL</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_007">8</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_008">SELLING SHAREHOLDERS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_008">9</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_009">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_009">11</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_010">WHERE YOU CAN GET MORE INFORMATION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_010">13</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_011">INCORPORATION BY REFERENCE</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_011">13</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_012">ENFORCEABILITY OF CIVIL LIABILITIES</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_012">14</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_013">LEGAL MATTERS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_013">14</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><A HREF="#a_014">AUDITORS, TRANSFER AGENT AND REGISTRAR</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_014">14</A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>You should rely only on the information contained or incorporated
by reference in this prospectus or to which we have referred you. We and the selling shareholders have not authorized anyone to
provide you with information that is different. This prospectus may only be used where it is legal to sell these securities. The
information contained in this prospectus may only be accurate as of the date of this prospectus and the information contained in
any document incorporated by reference in this prospectus is accurate only as of the date of that document, regardless of the time
of delivery of this prospectus or any sale of the common shares. Our business, financial condition, results of operations and prospects
may have changed since those dates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>References in this prospectus to &ldquo;ESSA&rdquo;, &ldquo;the
Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, and &ldquo;our&rdquo; refer to ESSA Pharma Inc. and its subsidiaries, unless
otherwise specified.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Unless stated otherwise or as the context otherwise requires,
all references to dollar amounts in this prospectus are references to United States dollars. References to &ldquo;$&rdquo; or &ldquo;US$&rdquo;
are to United States dollars and references to &ldquo;C$&rdquo; are to Canadian dollars. See &ldquo;Exchange Rate Data.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">i</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_001"></A>THE
COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a clinical stage pharmaceutical company focused on developing
novel and proprietary therapies for the treatment of prostate cancer in patients whose disease is progressing despite treatment
with current therapies, including second-generation anti-androgen drugs such as abiraterone, enzalutamide, apalutamide and darolutamide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further details concerning our business, including information
with respect to our assets, operations and development history, are provided in our Annual Report on Form&nbsp;20-F for the year
ended September&nbsp;30, 2019 (our &ldquo;Annual Report&rdquo;), as revised or supplemented by our subsequent quarterly reports
on Form&nbsp;6-K or Form&nbsp;10-Q, or our current reports on Form&nbsp;6-K or Form&nbsp;8-K, which are incorporated herein by
reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the
future. See &ldquo;Documents Incorporated by Reference.&rdquo; You are encouraged to thoroughly review the documents incorporated
by reference into this prospectus as they contain important information concerning our business and our prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our registered and records office is located at Suite&nbsp;2600,
Three Bentall Centre, 595 Burrard Street, Vancouver, British Columbia, Canada V7X 1L3. Our head office is located at Suite&nbsp;720
- 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have two wholly-owned subsidiaries, ESSA Pharmaceuticals
Corp., existing under the laws of the State of Texas, and Realm Therapeutics plc. (&ldquo;Realm&rdquo;), existing under the laws
of England and Wales. Realm has one wholly owned subsidiary, Realm Therapeutics Inc., a corporation existing under the laws of
the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are an &ldquo;emerging growth company,&rdquo; as defined
in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earlier of (1)&nbsp;the
last day of the fiscal year following the fifth anniversary of the completion of our initial public offering equity securities,
(2)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (3)&nbsp;the last
day of the fiscal year in which we are deemed to be a large accelerated filer, which will occur when the market value of our common
shares held by non-affiliates exceeds $700 million as of the end of the second quarter of any fiscal year and we have annual revenues
of over $100 million, and (4)&nbsp;the date on which we have issued more than an aggregate of $1.0 billion in non-convertible debt
during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_002"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing in our common shares is speculative and involves a
high degree of risk. Prior to making a decision about investing in our common shares, you should carefully consider the specific
factors discussed under the heading &ldquo;Risk Factors&rdquo; in the any applicable prospectus supplement and any free writing
prospectus, together with all the information contained or incorporated by reference in the prospectus supplement or appearing
or incorporated by reference in this prospectus, including the risks, uncertainties and assumptions discussed under the heading
 &ldquo;Risk Factors&rdquo; in our Annual Report, as revised or supplemented by our subsequent quarterly reports on Form&nbsp;6-K
or Form&nbsp;10-Q, or our current reports on Form&nbsp;6-K or Form&nbsp;8-K, which are incorporated herein by reference, and which
may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. These risks,
as well as risks currently unknown to us, could materially adversely affect our future business, operations and financial condition
and could cause purchasers of securities to lose all or part of their investments. The risks and uncertainties we have described
are not the only risks we face; risks and uncertainties not currently known to us or that we currently deem to be immaterial may
also materially and adversely affect our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_003"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus contains forward-looking statements or forward-looking
information within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities
laws. All statements in this prospectus, other than statements of historical facts, are forward-looking statements. These statements
appear in a number of different places in this prospectus and can be identified by words such as &ldquo;anticipates&rdquo;, &ldquo;estimates&rdquo;,
 &ldquo;projects&rdquo;, &ldquo;expects&rdquo;, &ldquo;intends&rdquo;, &ldquo;believes&rdquo;, &ldquo;plans&rdquo;, &ldquo;will&rdquo;,
 &ldquo;could&rdquo;, &ldquo;may&rdquo;, &ldquo;hopes&rdquo; or their negatives or other comparable words. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors that may cause the Company&rsquo;s actual results,
performance or achievements to be materially different from any future results, performance or achievements that may be expressed
or implied by such forward-looking statements. Examples of such forward looking statements include, but are not limited to statements
related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to maintain operations, development programs, preclinical studies,
clinical trials and raise capital as a result of the recent coronavirus disease 2019 (&ldquo;COVID-19&rdquo;) outbreak;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to obtain funding for operations, including research funding, and the
timing and potential sources of such funding;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the initiation, timing, cost, location, progress and success of, strategy and plans with respect
to, ESSA&rsquo;s research and development programs (including research programs and related milestones with regards to next-generation
drug candidates and compounds), preclinical studies and clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the therapeutic benefits, properties, effectiveness, pharmacokinetic profile and safety of the
Company&rsquo;s product candidate and potential future product candidates, if any, including the expected benefits, properties,
effectiveness, pharmacokinetic profile and safety of the Company&rsquo;s next-generation aniten compounds;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to advance its product candidate and potential future product candidates
through, and successfully complete, clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to achieve profitability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the grant (&ldquo;CPRIT Grant&rdquo;) under the Cancer Prevention and Research Institute of Texas
(&ldquo;CPRIT&rdquo;) and payments thereunder, including residual obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s use of proceeds from funding and financings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to effectively liquidate Realm and assume
the related obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s intended use of proceeds from the acquisition of Realm and the past and future
offerings of our securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to recruit sufficient numbers of patients for future clinical trials,
and the benefits expected therefrom;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to establish and maintain relationships with collaborators with acceptable
development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the implementation of the Company&rsquo;s business model and strategic plans, including strategic
plans with respect to patent applications and strategic collaborations and partnerships;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to identify, develop and commercialize product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s commercialization, marketing and manufacturing capabilities and strategy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to protect its intellectual property and operate its business without
infringing upon the intellectual property rights of others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s expectations regarding federal, state, provincial and foreign regulatory requirements,
including the Company&rsquo;s plans with respect to anticipated regulatory filings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in
the United States, Canada and other jurisdictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the accuracy of the Company&rsquo;s estimates of the size and characteristics of the markets that
may be addressed by the Company&rsquo;s product candidate and potential future product candidates, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the rate and degree of market acceptance and clinical utility of the Company&rsquo;s potential
future product candidates, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the timing of, and the Company&rsquo;s ability and the Company&rsquo;s collaborators&rsquo; ability,
if any, to obtain and maintain regulatory approvals for the Company&rsquo;s product candidate and potential future product candidates,
if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s expectations regarding market risk, including interest rate changes and foreign
currency fluctuations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s ability to engage and retain the employees required to grow its business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the compensation that is expected to be paid to the Company&rsquo;s employees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company&rsquo;s future financial performance and projected expenditures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developments relating to the Company&rsquo;s competitors and its industry, including the success
of competing therapies that are or may become available; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">estimates of the Company&rsquo;s financial condition, expenses, future revenue, capital requirements
and its need for additional financing and potential sources of capital and funding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Such statements reflect the Company&rsquo;s current views with
respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions
that are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties
and contingencies. Many factors could cause the Company&rsquo;s actual results, performance or achievements to be materially different
from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making
the forward-looking statements included in this prospectus, the Company has made various material assumptions, including, but not
limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">its ability to maintain operations as a result of the recent COVID-19 outbreak;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">its ability to conduct a clinical study involving its product candidate and to identify any future
product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the availability of financing on reasonable terms;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">its ability to repay debt;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">its ability to obtain regulatory and other approvals to commence a clinical trial involving any
future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">its ability to obtain positive results from its research and development activities, including
clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">its ability to obtain required regulatory approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">its ability to protect patents and proprietary rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">its ability to successfully out-license or sell future products, if any, and in-license and develop
new products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">favorable general business and economic conditions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">its ability to attract and retain skilled staff;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">market competition; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the products and technology offered by the Company&rsquo;s competitors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In evaluating forward-looking statements, current and prospective
shareholders should specifically consider various factors, including the risks outlined herein and in documents incorporated by
reference, under the heading &ldquo;Risk Factors.&rdquo; Investors should also consider the risk factors and uncertainties set
forth under the heading &ldquo;Item 3.D. Risk Factors&rdquo; in the Company&rsquo;s Annual Report, which is incorporated in this
prospectus by reference, as updated by the Company&rsquo;s subsequent filings under the Exchange Act and, if applicable, in any
accompanying prospectus supplement filed relating to a specific offering or sale. Some of these risks and assumptions include,
among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to maintain operations and execute on its business
plan as a result of the recent COVID-19 outbreak or other health epidemics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to conduct the clinical trial of its product candidate,
or submit a future Investigational New Drug application (&ldquo;IND&rdquo;) to the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
or a Canadian Clinical Trial Application (&ldquo;CTA&rdquo;) to Health Canada;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s future success being dependent primarily on identification
through preclinical studies, clinical studies, regulatory approval, and commercialization of a single product candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to identify any future product candidate through preclinical
studies and obtain regulatory approval of an IND/CTA ;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to continue to license its product candidates or technology
from third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">uncertainty related to the Company&rsquo;s ability to obtain required regulatory approvals for
its proposed products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to successfully identify and develop product candidates
in a timely manner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to clinical drug development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company's ability to successfully commercialize future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the possibility that the Company&rsquo;s product candidate and potential
                                                                                                               future product candidates, if any, may have undesirable side effects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to enroll subjects in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks that the FDA may not accept data from trials conducted in locations outside the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ongoing obligations and continued regulatory review;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential administrative or judicial sanctions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the risk of increased costs associated with prolonged, delayed or terminated clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the risk that third parties may not carry out their contractual duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the possibility that the Company&rsquo;s relationships with clinical research
organizations or academic institutions may terminate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s lack of experience manufacturing product candidates on a large
clinical or commercial scale and the Company&rsquo;s lack of manufacturing facility;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s failure to obtain regulatory approval in international jurisdictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to recently enacted and future legislation in the United States that may increase
the difficulty and cost for the Company to obtain marketing approval of, and commercialize, its product candidate and potential
future products, if any, and affect the prices the Company may obtain;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to new legislation, new regulatory requirements, and the continuing efforts of governmental
and third party payors to contain or reduce the costs of healthcare;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">uncertainty as to the Company&rsquo;s ability to raise additional funding;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to raise additional capital on favorable terms and
the impact of dilution from incremental financing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the acquisition of Realm, the liquidation of Realm, and the assumption of related
obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks that the Company may default on the residual obligations of the agreement providing for the
CPRIT Grant, which may result in the Company not receiving the remaining CPRIT Grant funds and/or having to reimburse all of the
CPRIT Grant, if such default is not waived by CPRIT;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s incurrence of significant losses in every quarter since its
inception and the Company&rsquo;s anticipation that it will continue to incur significant losses in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s limited operating history;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s reliance on proprietary technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to protect its intellectual property rights throughout
the world;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to claims by third parties asserting that the Company, or its employees or consultants
have misappropriated their intellectual property, or claiming ownership of what the Company regards as its intellectual property;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to comply with governmental patent agency requirements
in order to maintain patent protection;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to computer system failures or security breaches;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to business disruptions that could seriously harm the Company&rsquo;s future revenues
and financial condition and increase its costs and expenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s dependence on the use of information technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to attract and maintain highly qualified personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the possibility that third-party coverage and reimbursement and health care cost
containment initiatives and treatment guidelines may constrain the Company&rsquo;s future revenues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential conflicts of interest between the Company and its directors and officers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to competition from other biotechnology and pharmaceutical companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to movements in foreign currency exchange rates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to convince public payors and hospitals to include
the Company&rsquo;s product candidate and potential future products, if any, on their approved formulary lists;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to establish an effective sales force and marketing
infrastructure, or enter into acceptable third-party sales and marketing or licensing arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company's ability to manage growth;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to achieve or maintain expected levels of market acceptance
for its products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to realize benefits from acquired businesses or products
or form strategic alliances in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to collaborations with third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks that employees may engage in misconduct or other improper activities, including noncompliance
with regulatory standards and requirements, which could cause significant liability for the Company and harm its reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to product liability lawsuits;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to being able to obtain adequate insurance coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to compulsory licensing and/or generic competition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the increased costs and effort as a result of the Company being a public company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks inherent in foreign operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the possibility that laws and regulations governing international operations may
preclude the Company from developing, manufacturing and selling certain product candidates outside of the United States and Canada
and require it to develop and implement costly compliance programs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to laws that govern fraud and abuse and patients' rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to comply with environmental, health and safety laws
and regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the additional costs and expenses associated with being a U.S. domestic issuer
as opposed to a foreign private issuer;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company being a &ldquo;passive foreign investment company;&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s status as an emerging growth company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to United States investors' ability to effect service of process or enforcement of
actions against the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to maintain compliance with Nasdaq listing requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to market price and trading volume volatility;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company's dividend policy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks associated with future sales of the Company&rsquo;s securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company&rsquo;s ability to implement and maintain effective internal controls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the Company's ability to maintain an active trading market for its common shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to share price volatility associated with the Company&rsquo;s thinly traded common
shares; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to analyst coverage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If one or more of these risks or uncertainties or a risk that
is not currently known to the Company, materialize, or if its underlying assumptions prove to be incorrect, actual results may
vary significantly from those expressed or implied by forward-looking statements. The forward-looking statements represent the
Company&rsquo;s views as of the date of this document. While the Company may elect to update these forward-looking statements in
the future, the Company has no current intention to do so except as to the extent required by applicable securities law. Investors
are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly,
investors are cautioned not to put undue reliance on forward-looking statements. The Company advises you that these cautionary
remarks expressly qualify in their entirely all forward-looking statements attributable to the Company or persons acting on its
behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>EXCHANGE
RATE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We use the United States dollar as our reporting currency. The
following table sets forth for each period indicated: (1)&nbsp;the low and high exchange rates during such period; (2)&nbsp;the
exchange rates in effect at the end of the period; and (3)&nbsp;the average exchange rates for such period, for one Canadian dollar,
expressed in U.S. dollars, as quoted by the Bank of Canada. The average exchange rate is calculated on the last business day of
each month for the applicable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-size: 10pt">Low&#9;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">0.8138</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">0.7699</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">0.7710</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">High&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7330</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7353</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.6898</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Period End&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7330</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7699</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7497</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Average&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7721</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7537</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7437</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth, for each of the last six months,
the low and high closing exchange rates and the closing exchange rate at the end of the month for Canadian dollars expressed in
United States dollars, as quoted by the Bank of Canada:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Last Six Months</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">May</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">July</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">August</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">October</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 22%; font-size: 10pt">Low&#9;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.7265</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.7472</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.7485</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.7668</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.7660</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.7621</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">High&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7080</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7309</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7344</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7476</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7465</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7491</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">End of Month&#9;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7253</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7338</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7460</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7668</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7497</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.7509</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November&nbsp;24, 2020, the closing exchange rate
of Canadian dollars expressed in United States dollars, as quoted by the Bank of Canada, was C$1.00=US$0.7673.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_005"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will not receive any of the proceeds from the common shares
sold by the selling shareholders. We will not receive any cash proceeds from the selling shareholders in connection with the exercise
of the 2019 Pre-Funded Warrants issued pursuant to the August&nbsp;2019 Offering, which will be effected on a &ldquo;net&rdquo;
or &ldquo;cashless&rdquo; basis. We have agreed to pay all expenses in connection with the registration of the common shares offered
by the selling shareholders. Normal underwriting commissions and brokers fees, however, as well as any applicable transfer taxes
and other selling expenses, are payable by the selling shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our dividend policy is set forth under the heading &ldquo;Item
8.A. Consolidated Statements and Other Financial Information&rdquo; in our Annual Report, which is incorporated in this prospectus
by reference, as updated by our subsequent filings under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_007"></A>DESCRIPTION
OF SHARE CAPITAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are authorized to issue an unlimited number of common shares,
without par value. As of November&nbsp;19, 2020, there were 33,557,915 common shares issued and outstanding, 5,267,584 common
shares issuable upon exercise of outstanding stock options, and 7,779,473 common shares issuable upon exercise of warrants, including
the 2019 Pre-Funded Warrants. Of the outstanding warrants, 7,370,000 are pre-funded warrants, each exercisable at a nominal exercise
price into one common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of our common shares are entitled to receive notice
of any meetings of our shareholders, and to attend and to cast one vote per common share at all such meetings. Holders of common
shares are entitled to receive on a pro rata basis such dividends on the common shares, if any, as and when declared by our board
of directors at its discretion, from funds legally available therefor, and, upon the liquidation, dissolution or winding up of
the Company, are entitled to receive on a pro rata basis the net assets of the Company after payment of debts and other liabilities,
in each case subject to the rights, privileges, restrictions and conditions attaching to any other series or class of shares ranking
senior in priority to or on a pro rata basis with, the holders of common shares with respect to dividends or liquidation. Our common
shares do not carry any pre-emptive, subscription, redemption or conversion rights, nor do they contain any sinking or purchase
fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Registration Rights Agreement &ndash; August&nbsp;2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain of the selling shareholders acquired common shares and
the 2019 Pre-Funded Warrants pursuant to the August&nbsp;2019 Offering. In connection with the August&nbsp;2019 Offering, we entered
into a registration rights agreement with these selling shareholders on August&nbsp;27, 2019, pursuant to which we agreed to file
with the SEC a registration statement registering resales, from time to time, of the common shares and the common shares issuable
upon the exercise of the 2019 Pre-Funded Warrants issued pursuant to the August&nbsp;2019 Offering. We agreed to pay all expenses
relating to the registration required under the registration rights agreement, except for the underwriting discounts and selling
commissions payable by, and all legal fees and expenses of legal counsel for, any selling shareholder. We have filed the associated
registration rights agreement that contains these selling shareholders&rsquo; registration rights as an exhibit to the registration
statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>SELLING
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus covers the resale, from time to time, of up
to 7,370,000 common shares issuable upon the exercise of the 2019 Pre-Funded Warrants held by the selling shareholders named
in the table below after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling shareholders acquired the 2019 Pre-Funded Warrants
pursuant to the August&nbsp;2019 Offering. We have filed the associated registration rights agreement executed in connection with
the August&nbsp;2019 Offering as an exhibit to the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no assurance that the selling shareholders will sell
any of the common shares registered for sale under this prospectus. See &ldquo;Plan of Distribution.&rdquo; In addition, the selling
shareholders may have sold or transferred, in transactions exempt from the registration requirements of the Securities Act, some
or all of their registerable common shares since the date on which the information in the table below is presented. The common
shares listed below may be sold pursuant to this prospectus or in privately negotiated transactions. Accordingly, we cannot estimate
the number of common shares that the selling shareholders will sell under this prospectus. Information about the selling shareholders
may change over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table, to our knowledge, sets forth information
regarding the beneficial ownership of our common shares of the selling shareholders as of November&nbsp;19, 2020. Beneficial
ownership is determined in accordance with the rules&nbsp;of the SEC. Under these rules, beneficial ownership includes any common
shares as to which the individual or entity has sole or shared voting power or investment power and includes any shares as to which
the individual or entity has the right to acquire beneficial ownership within 60 days after November&nbsp;19, 2020 through the
exercise of any warrant, stock option or other right. The information provided in the table below is based in part on information
provided by or on behalf of the selling shareholders. To our knowledge, the selling shareholders have sole voting and investment
power with respect to the common shares and have not within the past three years had any position, office or other material relationship
with us (including any of our affiliates), except as set forth in the footnotes to the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Common Shares <BR> Beneficially Owned<BR> Before the Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Common<BR> Shares<BR> Being</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Common Shares<BR> Beneficially Owned<BR> After the Offering<SUP>(2)(3)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Offered</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Selling Shareholders</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; font-size: 10pt">Biotechnology Value Fund, L.P.</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">2,685,470</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><SUP>(4)</SUP></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">8.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">1,481,634</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">1,203,836</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">2.94</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Biotechnology Value Fund II, L.P.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,183,742</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.50</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,235,030</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">948,712</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.31</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Biotechnology Value Trading Fund OS, L.P.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">389,923</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(6)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">203,336</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">186,587</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Soleus Capital Master Fund, L.P.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,025,000</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(7)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.05</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">825,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">200,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Soleus Capital Special Opportunities Fund, L.P.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,675,000</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>(8)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9.99</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,625,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,050,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.56</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Less than 1.0% of total outstanding shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29px">(1)</TD>
    <TD>The percentage of common shares beneficially owned before the offering based on 33,557,915 common shares being outstanding as of November&nbsp;19, 2020, and assuming the issuance of that number of common shares equal to the full exercise of all securities convertible into common shares beneficially owned by each particular selling shareholder.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(2)</TD>
    <TD>The percentage of common shares beneficially owned after the offering is based on 33,557,915 common shares being outstanding as of November&nbsp;19, 2020, assuming the issuance of 7,370,000 common shares upon full exercise of the 2019 Pre-Funded Warrants.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29px">(3)</TD>
    <TD>The selling shareholders might not sell any or all of the common shares offered by this prospectus and as a result, we cannot estimate the number of common shares that will be held by the selling shareholders after completion of the offering. However, for the purposes of this table, we have assumed that, after completion of the offering, none of the common shares covered by this prospectus will be held by selling shareholders.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(4)</TD>
    <TD>Consists of 1,203,836 common shares and 1,481,634 common shares issuable upon exercise of 2019 Pre-Funded Warrants, provided that such 2019 Pre-Funded Warrants may not be exercised if, upon such exercise, the number of common shares then beneficially owned by Biotechnology Value Fund, L.P. would exceed 9.99% of our outstanding common shares (the &ldquo;9.99% Limit&rdquo;). Accordingly, Biotechnology Value Fund, L.P. disclaims beneficial ownership of the common shares issuable upon exercise of such 2019 Pre-Funded Warrants to the extent that upon such exercise the number of shares beneficially owned by it would exceed the 9.99% Limit. The address of the entity is c/o BVF Partners, LP, 44 Montgomery St, 40th Floor, San Francisco, CA 94104.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(5)</TD>
    <TD>Consists of 948,712 common shares and 1,235,030 common shares issuable upon exercise of 2019 Pre-Funded Warrants subject to the 9.99% Limit. Accordingly, Biotechnology Value Fund II, L.P. disclaims beneficial ownership of the common shares issuable upon exercise of such 2019 Pre-Funded Warrants to the extent that upon such exercise the number of shares beneficially owned by it would exceed the 9.99% Limit. The address of the entity is c/o BVF Partners, LP, 44 Montgomery St, 40th Floor, San Francisco, CA 94104.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(6)</TD>
    <TD>Consists of 186,587 common shares and 203,336 common shares issuable upon exercise of 2019 Pre-Funded Warrants subject to the 9.99% Limit. Accordingly, Biotechnology Value Trading Fund OS, L.P. disclaims beneficial ownership of the common shares issuable upon exercise of such 2019 Pre-Funded Warrants to the extent that upon such exercise the number of shares beneficially owned by it would exceed the 9.99% Limit. The address of the entity is c/o BVF Partners OS, LTD, PO Box 309 Ugland House, Grand Cayman, KY1- 1104, Cayman Islands.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(7)</TD>
    <TD>Consists of 200,000 common shares and 825,000 common shares issuable upon exercise of the 2019 Pre-Funded Warrants subject to the 9.99% Limit. Accordingly, Soleus Capital Master Fund, L.P. disclaims beneficial ownership of the common shares issuable upon exercise of such 2019 Pre-Funded Warrants to the extent that upon such exercise the number of shares beneficially owned by it would exceed the 9.99% Limit. The address of the entity is c/o Soleus Capital, LLC, 104 Field Point Road, Second Floor, Greenwich CT 06830.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(8)</TD>
    <TD>Consists of 1,050,000 common shares and 3,625,000 common shares issuable upon exercise of 2019 Pre-Funded Warrants subject to the 9.99% Limit. Accordingly, Soleus Capital Special Opportunities Fund, L.P. disclaims beneficial ownership of the common shares issuable upon exercise of such 2019 Pre-Funded Warrants to the extent that upon such exercise the number of shares beneficially owned by it would exceed the 9.99% Limit. The address of the entity is c/o Soleus Capital, LLC, 104 Field Point Road, Second Floor, Greenwich CT 06830.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_009"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling shareholders and any of their donees, pledgees,
transferees and successors-in-interest selling common shares or interests in common shares received after the date of this prospectus
from a selling shareholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer
or otherwise dispose of any or all of their common shares on any stock exchange, market or trading facility on which the common
shares are traded or in private transactions. These sales may be at fixed prices, at prevailing market prices at the time of sale,
at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. The
selling shareholders may use various methods when selling shares, including any one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>block trades in which the broker-dealer will attempt to sell the common shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>an exchange distribution in accordance with the rules&nbsp;of the applicable exchange;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>privately negotiated transactions;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>short sales effected after the date the registration statement of which this prospectus is a part is declared effective by the SEC;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>broker-dealers may agree with the selling shareholders to sell a specified number of common shares at a stipulated price per common share;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>a combination of any of the previously mentioned methods of sale; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>any other method permitted pursuant to applicable law.&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling shareholders may, from time to time, pledge or grant
a security interest in some or all of the common shares owned by them and, if they default in the performance of their secured
obligations, the pledgees or secured parties may offer and sell the common shares, from time to time, under this prospectus, or
under an amendment to this prospectus amending the list of selling shareholders to include the pledgee, transferee or other successors
in interest as selling shareholders under this prospectus. The selling shareholders also may transfer the common shares in other
circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for
purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the sale of the common shares or interests
therein, the selling shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which
may in turn engage in short sales of the common shares in the course of hedging the positions they assume. The selling shareholders
may also sell common shares short and deliver these securities to close out their short positions, or loan or pledge the common
shares to broker-dealers that in turn may sell these securities. The selling shareholders may also enter into option or other transactions
with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery
to such broker-dealer or other financial institution of common shares offered by this prospectus, which common shares such broker-dealer
or other financial institution may resell pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate proceeds to the selling shareholders from the
sale of the common shares offered by them will be the purchase price of the common shares less discounts or commissions, if any.
Each of the selling shareholders reserves the right to accept and, together with their agents from time to time, to reject, in
whole or in part, any proposed purchase of common shares to be made directly or through agents. We will not receive any of the
proceeds from this offering. We will not receive any cash proceeds from the selling shareholders in connection with the exercise
of the 2018 Warrants, which will be effected on a &ldquo;net&rdquo; or &ldquo;cashless&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay all fees and expenses in connection with the registration
of the common shares, other than the fees and disbursements of counsel to the selling shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling shareholders also may resell all or a portion of
the common shares in open market transactions in reliance upon Rule&nbsp;144 or Rule&nbsp;904 of Regulation S under the Securities
Act, provided that they meet the criteria and conform to the requirements of that rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling shareholders and any underwriters, broker-dealers
or agents that participate in the sale of the common shares or interests therein may be &ldquo;underwriters&rdquo; within the meaning
of Section&nbsp;2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the
common shares may be underwriting discounts or commissions under the Securities Act. Selling shareholders who are &ldquo;underwriters&rdquo;
within the meaning of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required, the common shares to be sold, the names
of the selling shareholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter,
any applicable commissions or discounts with respect to a particular offer will be set forth in an amendment to this prospectus
or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to comply with the securities laws of some states,
if applicable, the common shares may be sold in these jurisdictions only through registered or licensed brokers or dealers. In
addition, in some states the common shares may not be sold unless they have been registered or qualified for sale or an exemption
from registration or qualification is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have advised the selling shareholders that the anti-manipulation
rules&nbsp;of Regulation M under the Exchange Act may apply to sales of common shares in the market and to the activities of the
selling shareholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as it
may be amended from time to time) available to the selling shareholders for the purpose of satisfying the prospectus delivery requirements
of the Securities Act. The selling shareholders may agree to indemnify any broker-dealer that participates in transactions involving
the sale of the common shares against certain liabilities, including liabilities arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed to indemnify the selling shareholders against
liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the common
shares offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurance that any selling shareholder will
sell any or all of the common shares registered pursuant to the registration statement, of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>WHERE
YOU CAN GET MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have filed with the SEC a registration statement on Form&nbsp;S-3
under the Securities Act with respect to the common shares described in this prospectus. This prospectus, which constitutes a part
of that registration statement, does not contain all of the information set forth in that registration statement and its exhibits.
For further information with respect to us and our common shares, you should consult the registration statement and its exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are required to file with the securities commission or authority
in each of the applicable provinces of Canada annual and quarterly reports, material change reports and other information. In addition,
we are subject to the informational requirements of the Exchange Act, and, in accordance with the Exchange Act, we also must file
reports with, and furnish other information to, the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may read any document we file with or furnish to the securities
commissions and authorities of the provinces and territories of Canada through SEDAR at https://www.sedar.com. The SEC maintains
an internet site that contains&nbsp;reports, proxy and information statements, and other information regarding issuers that file
electronically with the SEC, where our SEC filings are also available. The address of the SEC&rsquo;s website is http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_011"></A>INCORPORATION
BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC allows us to &ldquo;incorporate by reference&rdquo;
into this prospectus the documents we file with, or furnish to, it, which means that we can disclose important information to you
by referring you to these documents. The information that we incorporate by reference into this prospectus forms a part of this
prospectus, and information that we file later with the SEC automatically updates and supersedes any information in this prospectus.
We incorporate by reference into this prospectus the documents listed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000110465919074530/tm1919820d1_20f.htm" STYLE="-sec-extract: exhibit">our Annual Report on Form&nbsp;20-F for the fiscal year ended September&nbsp;30, 2019;</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956920000172/essa6k.htm" STYLE="-sec-extract: exhibit">our Report on Form&nbsp;6-K, furnished to the Commission on February&nbsp;14, 2020, with respect to our condensed consolidated interim financial statements for the three months ended December&nbsp;31, 2019, and related Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations;</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956920000703/essa6k.htm" STYLE="-sec-extract: exhibit">our Report on Form&nbsp;6-K, furnished to the Commission on May&nbsp;7, 2020, with respect to our condensed consolidated interim financial statements for the three and six months ended March&nbsp;31, 2020, and related Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations;</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956920001172/essa6k.htm" STYLE="-sec-extract: exhibit">our Report on Form&nbsp;6-K, furnished to the Commission on August&nbsp;7, 2020, with respect to our condensed consolidated interim financial statements for the three and nine months ended June&nbsp;30, 2020, and related Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations;</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919002147/ex991.htm" STYLE="-sec-extract: exhibit">Exhibit&nbsp;99.1 of our Report on Form&nbsp;6-K, furnished to the Commission on October&nbsp;21, 2019;</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Exhibits <A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956920000227/ex991.htm" STYLE="-sec-extract: exhibit">99.1</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956920000227/ex992.htm" STYLE="-sec-extract: exhibit">99.2</A> of our Report on Form&nbsp;6-K, furnished to the Commission on February&nbsp;28, 2020;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000119312515241754/d873533d20fr12ba.htm" STYLE="-sec-extract: exhibit">the description of our common shares contained in our registration statement on Form&nbsp;20-F filed with the Commission on July&nbsp;1, 2015, including any amendment or report filed for purposes of updating such description.</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All documents filed by us pursuant to Sections 13(a), 13(c),
14 or 15(d)&nbsp;of the Exchange Act subsequent to the date of this prospectus and prior to the termination of the offering of
the common shares offered by this prospectus are incorporated by reference into this prospectus and form part of this prospectus
from the date of filing or furnishing of these documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any statement contained in a document that is incorporated by
reference into this prospectus will be deemed to be modified or superseded for the purposes of this prospectus to the extent that
a statement contained in this prospectus, or in any other subsequently filed document which also is or is deemed to be incorporated
by reference into this prospectus, modifies or supersedes that statement. The modifying or superseding statement does not need
to state that it has modified or superseded a prior statement or include any other information set forth in the document that it
modifies or supersedes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon request, we will provide, without charge, to each person
who receives this prospectus, a copy of any or all of the documents incorporated by reference (other than exhibits to the documents
that are not specifically incorporated by reference in the documents). Please direct written or oral requests for copies to our
Corporate Secretary at Suite&nbsp;720 &ndash; 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5, by faxing a written
request to 1-888-308-8974 or by calling 1-778-331-0962.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_012"></A>ENFORCEABILITY
OF CIVIL LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a corporation existing under the Business Corporations
Act (British Columbia) (the &ldquo;BCBCA&rdquo;). Many of our directors and officers are residents of Canada or otherwise reside
outside the United States, and all or a substantial portion of their assets, and a substantial portion our assets, are located
outside the United States. We have appointed an agent for service of process in the United States, but it may be difficult for
holders of our securities who reside in the United States to effect service within the United States upon those director and officers
who are not residents of the United States. It may also be difficult for holders of our securities who reside in the United States
to realize in the United States upon judgments of courts of the United States predicated upon our civil liability and the civil
liability of our directors, officers and experts under the U.S. federal securities laws. We have been advised by our Canadian counsel,
Blake, Cassels&nbsp;&amp; Graydon LLP, that a judgment of a U.S. court predicated solely upon civil liability under U.S. federal
securities laws or the securities or &lsquo;&lsquo;blue sky&rsquo;&rsquo; laws of any state within the United States, would probably
be enforceable in Canada if the U.S. court in which the judgment was obtained has a basis for jurisdiction in the matter that would
be recognized by a Canadian court for the same purposes. We have also been advised by Blake, Cassels&nbsp;&amp; Graydon LLP, however,
that there is substantial doubt whether an action could be brought in Canada in the first instance on the basis of liability predicated
solely upon U.S. federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_013"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain legal matters related to our securities offered by this
prospectus will be passed upon on its behalf by Blake, Cassels&nbsp;&amp; Graydon LLP, with respect to matters of Canadian law,
and Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP, with respect to matters of U.S. law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_014"></A>AUDITORS,
TRANSFER AGENT AND REGISTRAR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audited consolidated financial statements included in this
prospectus have been audited by Davidson&nbsp;&amp; Company LLP at its offices located at 1200 &ndash; 609 Granville Street, P.O.&nbsp;Box
10372, Pacific Centre, Vancouver, British Columbia, Canada V7Y 1G6, independent auditors, as stated in their report appearing therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Canadian transfer agent and registrar for our common shares
is Computershare Investor Services Inc. at its principal offices in Vancouver, British Columbia and Toronto, Ontario. The U.S.
transfer agent for our common shares is Computershare Trust Company, N.A. at its offices in Canton, MA, Jersey City, NJ, and Louisville,
KY.</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1.25in; text-align: left"><B>Item 14.</B></TD><TD STYLE="text-align: justify"><B>Other Expenses of Issuance and Distribution</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the estimated costs and expenses,
other than underwriting discounts and commissions, payable by us in connection with the offering of the securities being registered.
All the amounts shown are estimates, except for the SEC registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; font-size: 10pt; text-align: left">SEC registration fee&#9;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">US$</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: right">0</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Legal fees and expenses&#9;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">US$</TD>
    <TD STYLE="font-size: 10pt; text-align: right">50,000</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accounting fees and expenses&#9;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">US$</TD>
    <TD STYLE="font-size: 10pt; text-align: right">5,000</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Printing fees and expenses&#9;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">US$</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Miscellaneous&#9;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">US$</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt">Total&#9;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">US$</TD>
    <TD STYLE="font-size: 10pt; text-align: right">80,000</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1.25in; text-align: left"><B>Item 15.</B></TD><TD STYLE="text-align: justify"><B>Indemnification of Directors and Officers</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the BCBCA, we may indemnify all eligible parties against
all eligible penalties to which such person is or may be liable, and we must, after the final disposition of an eligible proceeding,
pay the expenses actually and reasonably incurred by such person in respect of that proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the purposes of such an indemnification:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;eligible party,&rdquo; in relation to the Company, means
an individual who</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&bull;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">is or was a director or officer of the Company; </TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&bull;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">is or was a director or officer of another corporation</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 0.25in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt">&bull;</TD>
    <TD STYLE="vertical-align: top">at a time when the corporation is or was an affiliate of the Company, or</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&bull;</TD>
    <TD STYLE="vertical-align: top">at the request of the Company; or</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&bull;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">at the request of the Company, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="4" STYLE="padding: 0.25pt">and includes the heirs and personal or other legal representatives of that individual;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;eligible penalty&rdquo; means a judgment, penalty or
fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo; eligible proceeding&rdquo; means a proceeding in which
an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible
party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer
of, the Company or an associated corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt">&bull;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">is or may be joined as a party, or</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&bull;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;expenses&rdquo; includes costs, charges and expenses,
including legal and other fees, but does not include judgments, penalties, fines or amounts paid in settlement of a proceeding;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;proceeding&rdquo; includes any legal proceeding or investigative
action, whether current, threatened, pending or completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, under the BCBCA, the Company may pay, as they are
incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible
party in respect of that proceeding, provided that the Company first receives from the eligible party a written undertaking that,
if it is ultimately determined that the payment of expenses is prohibited by the restrictions noted below, the eligible party will
repay the amounts advanced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">However, indemnification by the Company is prohibited under
the BCBCA if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">&bull;</TD>
    <TD STYLE="vertical-align: top">in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in good faith with a view to the best interests of the Company or the associated corporation, as the case may be; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">&bull;</TD>
    <TD STYLE="vertical-align: top">in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have reasonable grounds for believing that the eligible party&rsquo;s conduct in respect of which the proceeding was brought was lawful; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">&bull;</TD>
    <TD STYLE="vertical-align: top">the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that the agreement to indemnify or pay expenses was made, the Company was prohibited from giving the indemnity or paying the expenses by its&nbsp;&nbsp;articles; or </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">&bull;</TD>
    <TD STYLE="vertical-align: top">the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at the time that the indemnity or payment is made, the Company is prohibited from giving the indemnity or paying the expenses by the Company&rsquo;s articles. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, if an eligible proceeding is brought against an
eligible party by or on behalf of the Company or by or on behalf of an associated corporation, the Company must not do either of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt">&bull;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">indemnify the eligible party in respect of the proceeding; or</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&bull;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">pay the expenses of the eligible party in respect of the proceeding.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The BCBCA allows the Company to pay, as they are incurred in
advance of a final disposition of a proceeding, the expenses actually and reasonably incurred by the eligible party, provided that
the Company receives from such eligible party an undertaking to repay the amounts advanced if it is ultimately determined that
such payment is prohibited. Following the final disposition of an eligible proceeding, the BCBCA requires the Company to pay the
expenses actually and reasonably incurred by the eligible party in respect of that proceeding if the eligible party has not been
reimbursed for those expenses and is wholly successful, on the merits or otherwise, in the outcome of the proceeding, or is substantially
successful on the merits in the outcome of the proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding any of the foregoing, and whether or not payment
of expenses or indemnification has been sought, authorized or declined under the BCBCA, on the application of the Company or an
eligible party, the Supreme Court of British Columbia may do one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">&bull;</TD>
    <TD STYLE="vertical-align: top">order the Company to indemnify an eligible party against any liability incurred by the eligible party in respect of an eligible proceeding;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">&bull;</TD>
    <TD STYLE="vertical-align: top">order the Company to pay some or all of the expenses incurred by an eligible party in respect of an eligible proceeding;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">&bull;</TD>
    <TD STYLE="vertical-align: top">order enforcement of or any payment under an indemnification agreement; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">&bull;</TD>
    <TD STYLE="vertical-align: top">order the enforcement of, or any payment under, an agreement of indemnification entered into by the Company;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in">&bull;</TD>
    <TD STYLE="vertical-align: top">order the Company to pay some or all of the expenses actually and reasonably incurred by any person in obtaining an order under this section; or </TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&bull;</TD>
    <TD STYLE="vertical-align: top">make any other order the court considers appropriate. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The BCBCA provides that the Company may purchase and maintain
insurance for the benefit of an eligible party (or their heirs and personal or other legal representatives of the eligible party)
against any liability that may be incurred by reason of the eligible party being or having been a director or officer, or in an
equivalent position of ours or that of an associated corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s articles provide that it will indemnify
any of its directors, former directors, officers, and former officers and other parties specified by the articles against all costs,
charges, and expenses, including an amount paid to settle an action or satisfy a judgment, actually and reasonably incurred by
them for any civil, criminal or administrative action or proceeding to which they are or may be made a party by reason of having
been a director or officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has entered into indemnity agreements with each
of our officers and directors, pursuant to which the Company is obligated to indemnify and hold harmless such persons to the greatest
extent permitted by law for liabilities arising out of their service to the Company as directors and officers. However, such indemnification
obligations arise only to the extent that the party seeking indemnification was acting honestly and in good faith with a view to
our best interests, and, in the case of criminal or administrative actions or other non-civil proceedings that are enforced by
monetary penalties, that such person had reasonable grounds for believing that his or her conduct was lawful. Under these indemnification
agreements, the Company may advance to the indemnified parties the expenses incurred in defending any such actions or proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As permitted by the BCBCA, the Company has purchased directors&rsquo;
and officers&rsquo; liability insurance that, under certain circumstances, insures its directors and officers against the costs
of defense, settlement, or payment of a judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions,
the Registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the
Securities Act and is therefore unenforceable.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1.25in; text-align: left"><B>Item 16.</B></TD><TD STYLE="text-align: justify"><B>Exhibits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Exhibit<BR>
Number</B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 8%"><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000095012315003628/filename2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 90%"><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000095012315003628/filename2.htm" STYLE="-sec-extract: exhibit">Articles of Incorporation of the Registrant (incorporated by reference to Exhibit&nbsp;1 to the Registrant&rsquo;s Registration Statement on Form&nbsp;20-F, filed with the Commission on February&nbsp;24, 2015 (File No.&nbsp;001-37410)</A></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000119312518016237/d517730dex41.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000119312518016237/d517730dex41.htm" STYLE="-sec-extract: exhibit">Specimen Common Share Certificate (incorporated by reference to Exhibit&nbsp;4.1 to the Registration Statement on Form&nbsp;F-3 filed by the registrant on January&nbsp;22, 2018 (File No.&nbsp;333-222654))</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001838/ex992.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001838/ex992.htm" STYLE="-sec-extract: exhibit">Registration Rights Agreement, dated August&nbsp;27, 2019 (incorporated by reference to Exhibit&nbsp;99.2 to the Current Report on Form&nbsp;6-K furnished on August&nbsp;28, 2019).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001822/ex992.htm" STYLE="-sec-extract: exhibit">4.3</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001822/ex992.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Subscription Agreement for Common Shares (incorporated by reference to Exhibit&nbsp;99.2 to the Current Report on Form&nbsp;6 -K furnished on August&nbsp;23, 2019).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001822/ex993.htm" STYLE="-sec-extract: exhibit">4.4</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001822/ex993.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Subscription Agreement for Pre-Funded Warrants (incorporated by reference to Exhibit&nbsp;99.3 to the Current Report on Form&nbsp;6-K furnished on August&nbsp;23, 2019).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001822/ex994.htm" STYLE="-sec-extract: exhibit">4.5</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001822/ex994.htm" STYLE="-sec-extract: exhibit">Agency Agreement, dated August&nbsp;23, 2019, between Bloom Burton Securities Inc. and ESSA (incorporated by reference to Exhibit&nbsp;99.4 to the Current Report on Form&nbsp;6-K furnished on August&nbsp;23, 2019).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001264/ex992.htm" STYLE="-sec-extract: exhibit">4.6</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1633932/000127956919001264/ex992.htm" STYLE="-sec-extract: exhibit">Implementation Agreement, dated May&nbsp;15, 2019, between ESSA and Realm (incorporated by reference to Exhibit&nbsp;99.2 to the Current Report on Form&nbsp;6-K furnished on May&nbsp;28, 2019).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tm2037003d2_ex5-1.htm">5.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2037003d2_ex5-1.htm">Opinion of Blake, Cassels&nbsp;&amp; Graydon LLP as to the legality of the common shares being registered hereby.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tm2037003d2_ex23-1.htm" STYLE="-sec-extract: exhibit">23.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2037003d2_ex23-1.htm" STYLE="-sec-extract: exhibit">Consent of Davidson&nbsp;&amp; Company LLP.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tm2037003d2_ex5-1.htm" STYLE="-sec-extract: exhibit">23.2</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2037003d2_ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of Blake, Cassels&nbsp;&amp; Graydon LLP (included in Exhibit&nbsp;5.1).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="#POA" STYLE="-sec-extract: exhibit">24.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#POA" STYLE="-sec-extract: exhibit">Powers of Attorney.</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1.25in; text-align: left"><B>Item 17.</B></TD><TD STYLE="text-align: justify"><B>Undertakings</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned Registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>To include any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act of 1933;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
recent&nbsp;post-effective amendment&nbsp;thereof) which, individually or in the aggregate, represent a fundamental change in the
information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the
low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change in
the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration
statement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>provided, however</I>, that the undertakings set forth in
paragraphs (1)(i), (1)(ii)&nbsp;and (1)(iii)&nbsp;above do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section&nbsp;13
or Section&nbsp;15(d)&nbsp;of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement,
or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;that is part of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial<I>&nbsp;bona fide</I>&nbsp;offering thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(3)&nbsp;shall be deemed to be part of the registration statement
as of the date the filed prospectus was deemed part of and included in the registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7)&nbsp;as part of a registration statement in
reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii), or (x)&nbsp;for the purpose
of providing the information required by section&nbsp;10(a)&nbsp;of the Securities Act of 1933 shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness
or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&nbsp;430B,
for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new
effective date of the registration statement relating to the securities in the registration statement to which that prospectus
relates, and the offering of such securities at that time shall be deemed to be the initial<I>&nbsp;bona fide</I>&nbsp;offering
thereof. <I>Provided, however</I>, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus
that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date,
supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>That, for the purpose of determining liability of the Registrant under the Securities Act of 1933 to any purchaser in the initial
distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned
Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser,
if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: (i)&nbsp;any preliminary
prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;
(ii)&nbsp;any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or
referred to by the undersigned Registrant; (iii)&nbsp;the portion of any other free writing prospectus relating to the offering
containing material information about the undersigned Registrant or its securities provided by or on behalf of the undersigned
Registrant; and (iv)&nbsp;any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD>That, for purposes of determining any liability under the Securities Act, each filing of the Registrant&rsquo;s annual report
pursuant to section&nbsp;13(a)&nbsp;or section 15(d)&nbsp;of the Exchange Act (and, where applicable, each filing of an employee
benefit plan&rsquo;s annual report pursuant to section&nbsp;15(d)&nbsp;of the Exchange Act) that is incorporated by reference in
the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial<I>&nbsp;bona fide</I>&nbsp;offering thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD>Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers
and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that
in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act of 1933, and
is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Securities Act of 1933, and will be governed by the final adjudication of such issue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&nbsp;S-3 and has duly
caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vancouver,
Province of British Columbia, Canada, on November&nbsp;25, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ESSA Pharma Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/<I>David Parkinson</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>David Parkinson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="POA"></A><B>POWERS OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KNOW ALL PERSONS BY THESE PRESENTS, that each officer or director
of ESSA Pharma Inc. whose signature appears below constitutes and appoints David Parkinson and David Wood, and each of them, with
full power to act without the other, his or her true and lawful attorneys-in-fact and agents, with full and several power of substitution,
for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments, including post-effective
amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto, and other documents
in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power
and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully
to all intents and purposes as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents or his or her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act, this Registration Statement has been signed below by or on behalf of the following persons in the capacities indicated on
November&nbsp;25, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%"><B><U>Signature</U></B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%"><B><U>Title</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>David Parkinson</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Parkinson</P></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and Chief Executive Officer and Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>David Wood</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Wood</P></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer (Principal Financial Officer
        and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Accounting Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>Richard M. Glickman</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Richard M. Glickman</P></TD>
    <TD>&nbsp;</TD>
    <TD>Chairman of the Board</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>Marella Thorell</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marella Thorell</P></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>Alex Martin</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alex Martin</P></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><I>&nbsp;</I></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>Sandy Zweifach</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sandy Zweifach</P></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>Franklin Berger</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Franklin Berger</P></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>Scott Requadt</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott Requadt</P></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>Gary Sollis</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gary Sollis</P></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <I>Ari Brettman</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ari Brettman</P></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUTHORIZED REPRESENTATIVE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act, the undersigned
certifies that it is the duly authorized United States representative of ESSA Pharma Inc. and has duly caused this Registration
Statement to be signed on behalf of it by the undersigned, thereunto duly authorized, in the City of Houston, Texas on November&nbsp;25,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ESSA
    Pharmaceuticals Corp.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Authorized
    Representative)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    <I>David Parkinson</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>David
    Parkinson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>President
    and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm2037003d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 47.5pt; width: 155.05pt"></TD>
    <TD STYLE="width: 55%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; text-align: right; font-size: 10pt"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 72.35pt; width: 149pt"></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 47%; padding-right: 0; padding-left: 0; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-left: 0; width: 53%; padding-right: 0; text-align: right"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                     <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                     <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Reference: 99465/1</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">November 25, 2020</TD>
    <TD STYLE="padding-left: 0; padding-right: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ESSA Pharma Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Suite 720, 999 West Broadway</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vancouver, British Columbia V5Z 1K5</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RE: ESSA Pharma Inc. - Registration Statement on Form S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sirs and Mesdames:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have acted as Canadian
counsel to ESSA Pharma Inc. (&quot;<B>ESSA</B>&quot; or, the &ldquo;<B>Company</B>&rdquo;) in connection with the Registration
Statement on Form S-3 (the &quot;<B>Registration Statement</B>&quot;) filed on November 25, 2020 by ESSA with the U.S. Securities
and Exchange Commission (the &quot;<B>Commission</B>&quot;) under the U.S. Securities Act of 1933, as amended (the &quot;<B>Act</B>&quot;),
relating to the 7,370,000 common shares in the capital of ESSA (the &quot;<B>Shares</B>&quot;) that may be offered for resale by
certain shareholders of ESSA named in the Registration Statement (the &quot;<B>Selling Shareholders</B>&quot;). Certain of the
Shares (&ldquo;<B>Warrant Shares</B>&rdquo;) are issuable upon the exercise of common share purchase warrants (&ldquo;<B>Warrants</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This opinion letter is
being provided at the request of ESSA. As Canadian counsel for ESSA, we have examined a copy of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We are solicitors qualified
to practice law in the Province of British Columbia and the opinions expressed herein relate only to the laws of the Province of
British Columbia and the laws of Canada applicable therein as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have considered such questions of law,
examined such statutes, regulations, corporate documents, records and certificates, opinions and instruments and have made such
other investigations as we have considered necessary or desirable in connection with the opinions hereinafter set forth including,
without limitation, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a certificate of good standing dated November 24, 2020 issued by the Director or a Deputy Director
appointed under the <I>Business Corporations Act</I> (British Columbia) (the &ldquo;<B>BCBCA</B>&rdquo;) in respect of the Company
without any independent verification or inquiry (the &ldquo;<B>Certificate of Good Standing</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a certificate addressed to Blake, Cassels &amp; Graydon LLP executed by the Chief Financial Officer
of the Company as to certain factual matters (the &quot;<B>Corporate Certificate</B>&quot;), dated the date hereof, copies of which
are being delivered to you concurrently with this opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our examinations, we have assumed the
genuineness of all signatures, the legal capacity of all individuals, the authenticity and completeness of all documents submitted
to us as originals and the conformity to the originals of all documents submitted to us as certified, conformed, telecopies, facsimiles
or photostatic copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">51162989.3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Page 2</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have assumed the accuracy and completeness
of all facts set forth in the Corporate Certificate. To the extent the Corporate Certificate, and any other certificate or document
referenced herein, is based on any assumption, given in reliance on any other certificate or document, understanding or other criteria
or is made subject to any limitation, qualification or exception, our opinions are also based on such assumption, given in reliance
on such other certificate, document, understanding or other criteria and are made subject to such limitation, qualification and
exception. For greater certainty, where the Corporate Certificate affirms a state of fact, understanding or other factor based
on the belief, knowledge, awareness or understanding (or lack thereof, respectively) of the officer executing such Corporate Certificate,
we have assumed without independent verification that such belief, knowledge, awareness or understanding (or lack thereof) is and
remains fully accurate, correct and complete, that all covenants of the Company have been or will be performed as provided for
in the agency agreement dated August 23, 2019 between the Company and Bloom Burton Securities Inc. (&ldquo;<B>Agency Agreeme</B>nt&rdquo;),
that the Company and Realm Therapeutics plc (&ldquo;<B>Realm</B>&rdquo;) have complied with their covenants and obligations under
the implementation agreement dated May 15, 2019 between ESSA and Realm (&ldquo;<B>Implementation Agreement</B>&rdquo;), and we
have assumed that both the Agency Agreement and the Implementation Agreement have not been amended or supplemented, either orally
or in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the opinion expressed herein,
we have relied as to certain matters of fact on the Corporate Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Based upon the foregoing,
and subject to the qualifications, assumptions and limitations stated herein, we are of the opinion that: (i) the Shares, other
than the Warrant Shares, which may be offered for resale by the Selling Shareholders have been validly issued, fully paid and non-assessable
and will, when sold and paid for as contemplated by the Registration Statement, continue to be validly issued, fully paid and non-assessable;
and (ii) upon full payment therefor and the issue thereof in accordance with the terms of the applicable Warrants, the Warrant
Shares, which have been validly authorized and allotted for issuance, will be validly issued as fully paid and non-assessable common
shares in the capital of the Company and will, when sold and paid for as contemplated by the Registration Statement, continue to
be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this
opinion letter as Exhibit 5.1 to the Registration Statement and to the use of our name on the cover page and under the caption
 &quot;Legal Matters&quot; and &ldquo;Enforcement of Civil Liabilities&rdquo; in the prospectus included in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yours very truly,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<I>Blake Cassels &amp; Graydon LLP</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm2037003d2_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSENT
OF Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference
of our report dated December 18, 2019, relating to the consolidated statements of financial position of ESSA Pharma Inc. (the &ldquo;Company&rdquo;)
as of September 30, 2019 and 2018, and the related consolidated statements of loss and comprehensive loss, changes in shareholders&rsquo;
equity, and cash flows for the years ended September 30, 2019, 2018, and 2017 of the Company and the reference to our name in the
 &ldquo;Experts&rdquo; section in the Company&rsquo;s registration statement on Form S-3 filed with the U.S. Securities and Exchange
Commission on November 25, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&ldquo;DAVIDSON &amp; COMPANY LLP&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: justify">Vancouver, Canada </TD>
    <TD STYLE="width: 55%; text-align: right">Chartered Professional Accountants</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">November 25, 2020</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: fuchsia">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: fuchsia">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: fuchsia">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: fuchsia">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: fuchsia">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; color: fuchsia">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;<IMG SRC="image_006.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2037003d2_s3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2037003d2_s3img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !) /\# 2(  A$! Q$!_\0
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MRO\ *3LQS7X^?M>?\$A?C7^QU8W>JZQH$?B+PO9H99=<T%VNK6!!U:52JRQ
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M=O\ GOXU_P#!+_\ ;*/^(B']G;_GOXU_\$O_ -LK\4_U9S;_ *!Y_<S^@?\
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M 'Z7_"C^P[+_ )\[7_OTO^%?'_\ $45_T#?^3_\ VI]U_P 0>?\ T%_^2?\
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M[/?A#]I_X9WOA'QQHMMKFAWN&,,N0T,@!"RQN,,DBY.&4@\D="17Y*?M??\
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MPUDL<CP,_K,U=^])]%H?D?%F?RXBS&"PE-V2Y8K[3N^MC]GO^#>KPI<>'/\
M@G+I]W,C*FNZ_J%_ 2/O(&2WR/;= WY5]Q5RGP.^#^D?L_\ P?\ #?@K08O*
MTGPSI\5A;\ -($7!D;'\;MEF/=F)I_QL\):YX]^$/B71?#6NGPSK^JZ=/:V&
MK"+S3I\SH564+D<@GKU'4=*_#,SQ4<;CZE?93DWKT3?7Y']%91@Y8#+:6&MS
M2IP2TZM+6WJ]C\]_VXO^"]J_LY?MG6'A'PEINF>*?!GAEC;>*I8Y,S7=PQP\
M=O)]U3!CG.0SEE.W;FONS]FS]J[P!^USX$7Q#X \1V6NV0VBXB0[+FQ<C/ES
M1-AXVZ]1@XR"1S7\V_[37[+GCO\ 9*^)EQX8\?Z)=:1J@S)#*Q\RWU"/./.A
ME'RR(?4<@\$ @BL+X3?&KQ=\!_%::YX,\2:UX8U9%V?:M-NWMW=<@E&VD!E.
M!E6R#W%?J^*X P&*P5-X&=I)?%NI>;_1K;;4_%\'XEYEA,?568T[P;^#:4/)
M?JGOOI=G]5-%?@W\)/\ @X?_ &@/AUIJVNL-X1\;*O GU;3#%< >FZV>)3]6
M4GWKK/$G_!RW\9-1TUXM.\'_  ZTV9U*B=K:[G:/W4&<+GZ@CVKXZ?AYF\9\
MJ46N_-I^.OX'W4/%'(Y0YFY)]N77\&U^)^CO_!8+XQZ!\(?^">_Q&&MW5M'/
MXETN70],MI&'F7EU.NQ0B]24!:0^@C)K^<JO2?VD_P!KWXC_ +7?B>/5OB%X
MJU'Q#-;%OLL,A6.UL@V-PBA0"./.%R57)VC).*M?L=?LD^*/VTOCII/@GPQ:
MS%KN57U"_$1>'2;3<!)<2G@!5!X&1N8JHY(K].X;R:.1X"?UF:O\4GT6A^1\
M5Y]+B+,H?5*;M91BNKN^I^R__!O+X!NO!G_!.RUOKE&1/%'B&_U6WW#&8QY5
MKGZ;K9J^XKJZCL;62::1(H85+R2.VU44#)))Z "N7^!/P;T?]GGX-^&O!&@(
MZZ1X8T^*PMS)C?*$&#(^."[MEF/JQKYS_P""V/[4,7[-?[!_B6"WN_(\0>.5
M_P"$=TQ%?$A$P_TAQCD!8/,Y[,R>HK\5K\V;9M+V7_+V>GDF_P!%N?O^'Y,D
MR6/MO^7-/7S:73U>Q^(W[>7[2UY^UO\ M9>-/&]Q.TUIJ%^\.EKSM@L8CY=N
M@';]VJD^K,Q[UZ1_P1I_9IM_VG?V^/"=AJ-L;K0_#(?Q'J4>W*NEMM,2MVVM
M<- I'<,17RQ7[4?\&VW[-+>!OV>_$_Q+U"S\J]\;7PL=-E=?F:QM<AF4]E>=
MI ?7R%]J_;.)<7#*\FE&CIHH1^>GX*[^1_/O"6"J9QGT)5]?>=2?R=_Q=E\R
M#_@N3J%_)\9O!5K(9/[+BT626W!^[YS3L)<>^U(<_A7P]7[:?M>_L=>&_P!L
M+P-;Z9K,DNGZCIKM+IVIP(&EM"V-ZX/#(V!E<C[JG((KXYT7_@AEXB?Q1LU'
MQWHL>BAO]?;64KW3K_US8A5)_P!\X]Z_S8\0O#G/<9GM7&X*G[6%5IIW2MHE
M9W:M:VCVL?Z]^$OC!PQE_#%'+LRK>QJ4$TTXR?-[S=X\J=[WU6][Z6U.[_X(
M[Z'+\2?V3?'WAG7(GN?#&HZA-IZH_P!UTGM56XC'MM93CU<^M?B9^T=\$-3_
M &;/COXK\":PK?;_  OJ4MBSLNW[0BG,<H']V2,HX]G%?TT_ ;X&:!^SG\,=
M/\*>'('BT^Q!9I)&W2W4K??ED/=F/T X    K\D/^#DG]EV;P=\<_#?Q7L8#
M_9GC"U72=2D5>(KZW7]V6/K)!@ ?].S5_8/@9"MDN%HY+BI7;A;RYE=V7DDV
MEZ(_@3Z2->AQ%F&(XBP4.6/M&TNO([1NUW;2D^UV>6?\$$_VJXOV>/VV;;P_
MJ4XAT+XEP+H<K.V%CO-VZT<^I,A:(?\ 7QGM7[YU_)WX>U^[\*Z_8ZII\[VM
M_IMQ'=6TR?>AE1@R,/<, ?PK^G?]C;]I"Q_:V_9E\'_$"Q$<?_"06"R7<$9R
M+6Z0F.XB&><)*K@$]0 >]?6^)65\E:GCX+27NOU6WWK\CX/PFSGVF'J9;-ZP
M]Z/H]_N>O_;Q\'_\%QO^"<OQ@_;*_:$\):[\.O"T6NZ7I?AT6%S,VJ6EIY<W
MVF9]NV:5&/RNIR!CGK7Q1_PXF_:A_P"B=6__ (46F?\ R17]"E%>)EW'>88+
M#0PM*,'&.BNG?_TI'T.:^'&69ABYXRM.:E-W=G&W_I+_ #/YZ_\ AQ-^U#_T
M3JW_ /"BTS_Y(H_X<3?M0_\ 1.K?_P *+3/_ )(K^A2BNW_B)6:?R4_NE_\
M)'G_ /$)LG_GJ??'_P"0/YZ_^'$W[4/_ $3JW_\ "BTS_P"2*/\ AQ-^U#_T
M3JW_ /"BTS_Y(K^A2BC_ (B5FG\E/[I?_)!_Q";)_P">I]\?_D#YJ_X)(_L]
M>+?V7/V&_#7@WQOIBZ/XBT^[OI;BU6ZBN0BRW4DB'?$S(<JP/!XSS7TK117P
MV-Q4\5B)XFIO-MNVVNI^B8#!PPF&IX6E?E@E%7WLE;4XGX\?LX^!OVG?!3>'
MO'OAG2_$VD[MZ17<?SV[XQOBD4AXGP2-R,#@]:_/'X_?\&SOA?7KB[O/AMX^
MU+P^SL7ATW6K87MNN>B"9"DBJ.Q99#ZYZU^HE%=V6Y]C\OTPM5Q7;=?<]#SL
MVX;RW,]<;24GWV?WJS_0_!;QO_P;Q_M$^%KQTTZT\(>)(@?EEL-96(,/I<+$
M163H7_! 3]I;5[I8[CPOH6EH3@RW6OVK*ON?*=V_(5^_]%?3KQ'S51LU#UL_
M\SY&7A5DKES)S7ES+_Y&_P")^0_P(_X-DM3N98KCXF?$>SM(PP,EAX:M6F=U
M[C[1.%"G_MBPK]*_V7OV/OAY^QQX);0OA_X=MM%M[C8UY<9,MWJ#J,!YI6RS
MGEB!]U=QV@ XKTVBOG<TXCS',5RXJI>/9:+[EO\ .Y]3D_"N5Y6^?"4DI?S/
M5_>]OE8****\,^A.*^._[.?@C]ISP2WAWQYX:TSQ+I);S$BNX_F@?&-\4BD/
M&^"1N1@>>M?G;\>_^#9KPSK=S<W?PW^(&I:#O)>/3M;M1>P@G^$3QE'51_M(
MY]S7ZCT5Z^6Y]C\OTPE1Q7;=?<[H\/-N&\MS/7&TE)]]G]ZLS\%?&W_!O'^T
M5X7NV33[3P?XDC'W9+#6EC#?A<+$:R]"_P"" G[2VKW2QW'A?0M+4G!ENM?M
M65?KY3N?TK]_J*^G7B/FJC9J'K9_YGR,O"K)7+F3FO+F7_R-_P 3\BO@'_P;
M*7\\\-S\3OB+:V\((,FG^&K=I7<=Q]IG50I_[8M7Z4?LO_L>?#O]CGP5_8?P
M_P##EIHT,P3[9=8\R\U%ESAYYF^9SRQ SM7<=H XKTVBOG<TXCS',%RXJI>/
M9:+[EO\ .Y]3D_"N5Y6^;"4DI?S/5_>]OE8*_,?_ (+8?L+?'S]N;XZ>'4\$
M^%;>^\%^$M,,5K--K-I;_:+J=@T[B.216 VI"G(_Y9D]"*_3BBN;*,UJY=B5
MBJ*3DKVO?KZ-'5GF34<UPCP>(E)1;3?*TF[:VU3TN?S\0_\ !!+]IN695;P5
MI<:LP!=O$%CA1ZG$I/Y"OW<^!GPET[X#?!OPOX,TE%73_#&F0:="57;YGEH%
M+G_:8@L3W+$UU=%>AGG%&,S:,(8FR4;OW4UOWNV>9P[P?@<EE.>$<FYV3YFG
MHNUDM^OH@HHHKYP^J"OG[_@I[^R3/^VE^QKXG\':;'$_B*,1ZGH?F,J WL!W
M*FYB OF(9(MQ( \W)Z5] T5T83$U,-6AB*7Q1::^1S8W"4\5AYX:LKQFFGZ,
M_GU_X<+?M.?]"/IO_A0V'_QVOTK_ .")/[-_QF_9%^$_BCP-\4/#]MI>CK?I
MJ>A3Q:G;W9W2KMN(2(G8JH,<;C/=Y*^WZ*^FS;C/&YCAGA<1"'*[/1.ZMV]Y
9GR.2< Y?E6+6,PLY\RNM6K-/O[J]=]S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !C 4,# 2(  A$! Q$!_\0
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MW6W;?<?:KUI<1XX+#L2<8 [9]JU?V=%UV?5-3N7N+DZ,D/EE9&)1IB01MSW
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MG6/B?XEAM+.&;['YOEV-@G)8GC<P[L?T'XFK/Q5^)5QX[U@6.GF1=%MY,01
M',[]-[#^0[#W->O_  <^%R^%+!=;U>$'6KE/D1AG[*A_A_WCW].GKD U?A=\
M,K7P+I8N+H)-K=PG[^8<B(?\\T]O4]S^%>AT44 %%%% !1110 4444 %%%%
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MIGQ%XONAK&NR-YI#_-%$WKS]XC\AV%>E:IJ5IH^EW.I7THBM;:,R2.>P']:
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MJ"^(=7ASI-J_[F-QQ<R#^:COZGCUKV+X@_%;1O L36PQ>ZN5REG&V-GH7/\
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MY5!+'.K$H54+\N.HP!Z4 <G\&]?\%^"]!O\ 7=8U%!J\KF%(%0M*L0P<*/\
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MV I]%% !7C_Q2^%?B+QYXDM[NUU:TCL(81''!.6'EGJQP <YX_*O8** /)?
M_P "='\-W<>H:Q.-6O(\&-&CVPQGUVG.X_7\J]:HHH **** "BBB@"MJ!O!I
MUR=/6)KWRF\@3$A"^/EW8[9KYZM/@)XIU[7)M0\4:M;0^?*9)Y(F,LCDGG'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J=YI&FZ@<WNGVES_P!=H5?^8HHH
M =9Z9I^G*5L;&VM0>H@B5,_D*M444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #C <<# 2(  A$! Q$!_\0
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M(-'AM;V[TG>YLKM]BS"1 "0W(##'!- &YH7C3P[XEN)+?2-4BN)XUW/#M9'
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MGEN_!W@_1=&\-N([R>[M].M9)5#D G+,0>ORJQ-=S2%%8J64$J<@D=#0  $
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M60,K*2H.TY.>>U>BT4 >97 7P1XUUF\U'1;B^T/6'2Y2ZMK4SFVF"[75U )
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M*1DPN"3C@+DXS1XVN7T7QQX7U^:SO)].MX[N"XDM8&E,1=4VDJH)P<&N_HH
M\\UUKW3/%>E^.].TZ\OK"?3_ +'?VT,1\^.(MYB2",\D@D@CJ*J:YJ<OQ)FT
M_0](TW4(]*6[CN=1OKNV>!!'&V[RT# %F) [<5Z=10!Q\=E=#XR3WYMIOL9T
M".$7&P^69!<.2N[INP0<=<5+XF\1ZGX=UFSEDTF:]\/2PLMS+:0-+-!+G@LH
M/*$>@ZUU=% 'E=G;6_B/XC:3K7AK1;G3+6TBG^W:A)9FV6YWKA$"D N0><D<
M45ZI10 4444 %%%% !1110 4444 %%%% !1110 4444 <WXJ\80>%9-.ADTZ
M^O[C4)&C@ALD5G)49/!([5E'XGV=GM?6O#_B#1[8D W5Y9?NDSP-S*3BJ7Q'
MO[32_%W@:]O[F.VM8KZ<R2RMM51Y6.3^-2>*?B-X2N?#E_86>I0:M=WEN\$%
ME9_OGF=E( PN<=>] '?Q2QSQ)+$ZO&ZAD=3D,#R"#Z4^O/\ 3U\5>'O!7A;0
M-,L(YM5D@6*>YN0S06:JN3OV\D_P@9Y(J>QUSQ-HWB_3-#\2-IUY!JJ2_9;N
MRB:(I)&NXJZL3P1T(- ';F1!((RZAR"0N>2!U.*=7D5ZOCC_ (6_$(9- ^U_
MV3*8=ZS>7Y'G#[V#G?G'3BNM\0^)-877K/PQX>@M)-7FM_M5S<7.XPVL0.W<
M0.6);( _.@#L**X>UU_Q)H/B33])\4BPN;74V:*TU"R1H]LP&[RY$8GJ <$'
MM4-]XH\377CW4O"NB6M@OD6\,ZWMR&*PJP.[< ?F).-H&.^3Q0!WU-\Q/,\O
M>OF8W;<\X]<5QV@Z]K]MXLD\,^)5LI;B2U-W9WEFK(DJ!@K*RL3A@2#P<8KE
M+-?'/_"V[T>9X?\ MG]EP^;\LWE^3YK8V\YWYS[=* /7JYWQ3XNMO#!LH/L=
MU?ZA?R-':65JH+RE1ECR0  .IKHJ\U^*UW%IEUX>U:PF#^)+&Z+6%@BEWNT<
M;94VKD@%?XNV/>@#H_#7C.'Q!J-YI5QIMYI>K6:K)+9W:C.QNC*02&%=/7G'
MPT)UZ;4_'-]<Q2:C>_Z,;6+(%C'&?]4V<'=GDY'TKK/"/B%?%?ABSUM+5K9;
MG>5B9]Q 5V7.<#KMS^- #?$7B.;06MQ%H&K:KYP8DZ?"'\O&/O9(QG/'T-<U
M#\5?M%_<V,/@WQ,]W:A3/"MLA:,,,KD;^,BO0JX7PY_R5OQM_P!<;#_T6U '
M4Z)JDFL:8EY)IUYI[,Q'V>\0)(N#C) )ZUHUY_>^)/%>H>.]6\,:'#IT,=G%
M!-]NN4=A&KKDJ5!&YB>G0  YK2U:]\8/J%EH^CP6:2"U$UYJMU"Y@#]-D:@C
M+$Y.">!0!UU%<=X<U[7%\5W?A?Q&ME)=QVBWMO=V:LB2Q%MA#*Q.&#>]9]IK
M_B[Q;>WUQX:;2K+1[2X>VBFO8GE>[=#AF 4@*F> >30!UEKK]M=^)-1T-(Y1
M<6,44LCL!L829QCG/\)[5JUYEX&U&^O?B5XN?5[1+*]M[6TBN$1]T9*A_G4G
MG:001GGFK>G:YXT\802:MX>;2=/T<NRV?VZ)Y)+I5)&\[2 BDCCJ: /0J*YS
MP?XEG\06EY#J%HMGJVG7!M;V!&W*' !#*>ZL""*O>)]3FT7PMJNJ6RHT]I:2
MSQK("5+*I(!QVXH U:*\ZL]6^(>N:!;Z_IT.BVT,L"S0Z?<)(TDRXSDN&PA;
MJ!@X!&32Z3XF\6>.=(CU;PW%IVE617:/[1C>5YI!]\ *0%0-E<\DX/ H ]$H
MKD_#OBV\U3PIJ%]=:8W]K:9+-;75E;9;?-'VC]0V1CZUAWVK?$;2_#\OB2Z3
M0S#!#]IFTH12"1(P,LOF9^^!GMC(H ](K*\2Z_;>%_#]UK-Y'+)!;!2Z1 %C
MN8*,9('5A7.^+O&M]I&C>'M0T6RCO&U>ZBACAER"PD0LN"#P<XR>>,UC^/H?
M$$7PCU\^(;NPGN&,)0643(B#S4R/F))Y[\4 >GT5R6I>*KJ[UPZ!X7AAN[^)
MA]MNILFWLE]&P06<]D!^N*ZQ<A0&(+8Y(&,F@!:YCPIX[TGQA=:E!IRSJUC(
M%)E4 2J2P#ISRI*GFF?$/5Y]*\(7$=B?^)CJ#K860!Y,LIV@CZ#+?A7.7^E0
M?#_Q%X/U"T^6P,*Z%>-C&0W,3G_@8.3_ +5 'IM%<YXT\3OX7T>&6UM/MFI7
MEPEI96V[ DE?ID]@,$GZ5S&O:]X_\'>'[K6M3CT;4X(X6+QVD4B-;N1\K<M\
MZ!L ]#CF@#TJBN,U;QC>6?A[0#96<5UKNN)&MK;EBL88H'=V/4(H.3WZ51O]
M=\8^#Q;ZCXC;2=0T9I4CNI+*)XI+3<0H?#$AD!(ST- 'H-%<5XM\5ZUI/BO1
M-#T:QMKJ75(9BIF+*(V3:0S$'[@!)(QDX '6H$USQ7X=\1Z59>)6TR\T_593
M;17-E$\303;255E8G*G! - '=-(B,BLZAG.%!/+'&>/7BG5Y1XP'C#_A:'A;
M[+)H@S)>_P!G>8LO"^2-WFX/7'3;WKH?$'B/7[/4M!\.:>NFC6]2A>2:YGW^
M1$(U!?:N=S$DG SVYH [:BN0T:]\86?B1-+U^VM+VRGA:2+4K")XUC=?X)%)
M.,CH0:* .OHHHH **** "BBB@ HHHH **** "BBB@ HHHH \_P#'T,5QXW\!
MQ3Q)+&U].&1U# _NCU!KM[;3[*S)-K9V\!/4Q1*N?R%)<Z;97EU:W-S:Q2SV
MC%[>1UR8F(P2I[<<5:H \]\:7%SJ7CC0_"TFK7.E:9>6\MQ++;2>5)<NI $2
MOVX.3CK6!<Z1H.@_%_P;I^EW5U/>9NI+@3WLD^Q3"VW.XD*3\WITKT_6O#VD
M>([1;76-/@O(5;<JRKDJ?4'J#]*K:=X0\.Z1]G^P:/9V[6SM)$Z1C<K,-I;=
MU)(XR>U &#=R)%\;]/\ ,=5\S0953<<;B)E) _#FN?U_1K2;XRL-4U74=-AU
M/38Q9SVEV;<221L0T98=3@A@/>O0==\*Z%XF$/\ ;.F07A@),3."&3/7!&#@
M^E2ZIX>TC6M,73M3TZWNK1 -D4J9"X& 0>H..XH X"]\.>'M.\7^'M/DU;Q#
MJNI-="YAMY-1,JP>6"WFNIZ+V]3G K;T/_DKWBW_ *\K'^4E;VA^$] \-F1M
M'TJVM'E&'D1<NP]"QR<>V:T(M/LX;^>^CMHTN[A52:8+\SA<[03WQD_G0!R.
MJ?\ )9?#_P#V"KO_ -#CIMM(B?&[45=U5GT*$J"<9Q,^<5V#Z?9R:A%J#VT;
M7D*-'',5^95;&0#Z' _*L[6O".@>(KB"XU;2X+J> 8CD<$,HZXR",CVH VJ\
MPT6ZL;#XU>)5UUTBU&XB@_LJ6X. UOM^98R>,[NH')P?>O3ZS-:\.Z-XCMEM
M]8TVVO8U.5$R E3['J/PH \M^)4J^%=8EU7PG>1_VUJL3P7FDP@R&Y78?WX5
M?NLG7)Z_GGOOAVVF'X?Z(FDW*W-K%:HGF#@EP/FR.QW9XJWH7@[P[X9=WT;1
M[6SD<8:1$RY'IN.3CVS5[3M&TW2//_LZR@M1<2&640H%#N>K$#O0!>KA?#G_
M "5OQM_UQL/_ $6U=U5:'3K.WO[F^AMHDNKD*)YE7#2!1A<GO@4 <CX?_P"2
ML^,O^O>P_P#0'K,U-)/%?Q-U#P]J.L7NGZ=I]I#-!:6EP8&NR^=SLPY*KTP*
M]!BT^S@OKB^BMHTNKD*LTRKAI O"@GOC)K/UWPEH'B5HFUC2K>[>'B-W&&4>
M@88./:@#S_PK9Z-I_P ;KZPT6XGFC@T(I.\MR\Y$GG(2 S$] 1P.];'PGN8;
M+PK<:#<2)'J&D7EQ#<QL<,,R,ZOCT(;@]#76Z=X<T72)8I=.TNTM9(H3;HT,
M04B,MN*\=BW/UJIK/@CPSX@O5O-5T:UN;D +YK*0S = 2,;A]<T <5X>U"V\
M4?$'Q^--E5HI+*"VBG7[KD*Z%@>XW9&?:L[X>>%M+U;PA;+)XDU^SO;(&WO;
M./5&C%M(A((V?PCC(KU>RT73--G::QL+:VD:)82T,87Y%SM7CL,G K*U;P%X
M5UR_-]J6AVD]TPPTI4J7_P![!&[\<T <KX3\.Z#K5IXA32M0U\P2WB12ZF;X
M[[AXAUCD')4;MI/?'M5S7?"5OX<\">*98=4U>\,NESJ5O[QIE7"$Y /0UW5I
M9VVGVD5I9V\5O;Q+MCBB0*JCT '2G75K!>VDUK=1)-;S(8Y(W&5=2,$$>E &
M=X8X\(:/_P!>$'_HL5SWPC_Y)CI'UF_]'/79PPQ6\$<$**D4:A$11@*H& !^
M%16&GVFEV4=G8VT=O;1YV11+M5<DDX'U)- 'E8UF^\/>$?B3JFFJ#>0:U,8R
M5SLR(U+8]@2?PJ#Q9X8\.Z7\.[_6+WQ#J>J7<UFWDW$NIR$3RLOR[44@$$GI
M@\=:]9ATJPMTNTBLX%2\D:2Y4(,2LPPQ8=\@8K$L_AYX0T^:66V\/6*/*C(V
M8]P"L,, #PH()'&* .5U,?\ %/\ PN_Z_K+_ -)VK8^+XS\*];![K#_Z.2NK
M;1].>&RA:RA,=BRO:J4&(2HPI7TP.*DO]/L]4LI+*_MH[FVEQOBE7<K8((R/
MJ : . T<GX8:H-$O<'PU?W!:QOR/F@F<Y,4Q[Y/W7/T/MZ15>^L+34[*6SOK
M:*YMI1MDBE4,K#W!J6&&.W@C@A4)'&H5%'8#@"@#S7Q+::CXS^)4&F:5JATZ
M/P[ +F6Y6!9L7,O"+M;C(0$Y[9H\1_#SQ9KN@7=A=>.I+M'3<L+:9#&&=?F7
MYE.5^8#D5Z':Z;96,]U/:VL4,UT_F3NBX,K8QECWXJU0!XYJGB-]4\(>"/&=
MQ&[)I>H*-54+DPG!CD<CV;G\170?$OQ?HB?#C54MM0MKR:_M'BMXK>02,X93
ME@!V498GMBMS7]/OM(T&X;PGI-A+/+=?:+JSD4*MTK?ZP \ .1CD\<5P]Y92
M:MIEWH_AGX</H5YJ49MKJ_N;:&".")N'(*DE^"< 4 1>*+"!D^&^H:A>W=CI
MB6QM9KNUF,+0/)"FPEQT!*D$U:\7>%?#>EZ,B:AKWB;4A>R)!!8+JI=KIF8
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M3V-]*)I+8(N5</C(4GY<']>Q7;:'X4T'PWYAT?2[:T:7[[HN78>A8\D>V:*
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M'#?16AD",B_*\O4*.1R>N#5G0/'$%SX+EUB^L]5A6PLTEN9+FS,9F^3+-'G
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MYDNIM!NEBAGD.7>W<;HMQ[D $?E7>T (2%!)( '))K'_ .$N\-'_ )F'2?\
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M,'^O$-IIWB+Q=XRTO6M<TD:-I>C[Y+6T>=999YF&W>VWA0!T'7/UH ?\+O\
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MR_V9W5HXKBW_ ('5B2"?7G^N*?A^^B\5?%NX\0Z(KMHUKI?V*6]V%4NI3)N
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M.L6,J+'=PWT2;D!88>-D (PV,J<C!-=YXF@U^\DL+;3=232-,V,]]J V&50
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M?C=F73C=RF#CG&S=@C/8\444 =G8:'ISZ#X4TIK?=817<DJP%V*EE9F7//S
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..DDN.F68DX]J*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, Y$# 2(  A$! Q$!_\0
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MHH :A&T#/('-.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH1RQ7U7(3(Z'GWKHO"EY<7O]L2W4+P3B^"21MG"LL$0;;ZJ2"0?>@#H:***
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MKDK:;J\AM&M[O3XV+1R,&!.S>IR#R",5)_:<W]H:1!M3;>0R22''(*JI&/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  N U(# 2(  A$! Q$!_\0
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M/<IBD1DD.U7!0L#^#G[#_P#P3"\'?LE?\%@?^"AO[3OPR^ >D_"+X+_%_P"
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M!# AL%2""&!&001P<CD8ZCD<4$A>I R<#) Y].>] "T4F0>A!QUY%!(4$L0
M.220  .223QTH 6BC_/Y=:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW\%;[QIXC^!7@K7M4^+7@/XN>(_&/A ^*M%^,7@3X>77@CP'XKT?Q=]J\1^
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M3Q%I'C+PKX;U&VGM%U?P=XSO-0AU"TU"QCL0#\'_ /@FM^VM^U)\.+CX9?\
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MZ\(?L2? K_@H9X%_X+<_LM_M#>'X]9\'>./^"GOB2?1=>B@M9?%7PW\;Z?\
ML%_L,)X3^)/@/4+R.5M(\6>%;J[;[%-&1;:GI%YJGA76(;_PSK^LZ5??.?\
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M&G6VNV'B^#2_JK_@BU%'+_P3Q^'22(K+)\;OVX%=3M(8']N;]HP8PN%QB/'
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M]4O]"BU'13KMCIUZ\%W<Z5%J^E'5+>%[5-4L_/%Y'^?'_!,/X"ZM\-_@!/\
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M551V <[B02=Q);G.57DDC^%0<Y50N )BP'4_SH 6BF[U]?T/^%&]?7]#_A0
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M-X#\:KX<^(6CZQ\-M8.A^*]>/A+QF83XAT>]M[*XTZZ /UXHKYV_:.^,^K?
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MXIU[PU;?U$A57.U0,]< #.  ,XZX  ^@ [4T1QA@PC0,"Q#!%# OC>00,Y;
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M%\(0^(CH-C(T_AU]8@T>YOK^YM+N=/T*;6O^"GG[1W[1_P"R3;_$G]DKP?\
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M  P3_P %;/\ I(9_P6R_\(S_ ()]?_1W4?\ #!/_  5L_P"DAG_!;+_PC/\
M@GU_]'=7]?\ @>@_(48'H/R% '\@'_#!/_!6S_I(9_P6R_\ ",_X)]?_ $=U
M'_#!/_!6S_I(9_P6R_\ ",_X)]?_ $=U?U_X'H/R%&!Z#\A0!_(!_P ,$_\
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M'(/#OQ!CU&SU"]BT&6;7VZY/V+_BC>W'PZ^%'Q[_ &3_ (\^,_A=XW_X)O\
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MG_!/K_Z.ZOZ_\#T'Y"C ]!^0H _D _X8)_X*V?\ 20S_ (+9?^$9_P $^O\
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CB"XFB"R-NE5/55/U I0      , #@ #H .P% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !< 8D# 2(  A$! Q$!_\0
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MS#&9#PU1S;-89-"6(E4Q%/#2E@ZV$AB*9QW[,VO'X;_&+4?V//\ @HY^SO\
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MS^ _#WBSPOK5KXG;3]8NOA9XF&HZ9\2?!MKI_P#0J(H@"!%& P4, B@$( J
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MA^%NKWCZ58Q:SH^G1 'Y=_LQ_L_ZSX>\&Z!X-^/'Q*\4_LG:#<?\$O?V*O\
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M&]$;!!&Y0V",D$9!P022#U&3CK08XSLS&A\H@QY13Y9 V@IQ\A X!7&!QTH
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MH5QI'A_3;^^GTC2_,@T]+'3;*YU&WTW5[C3],WQP6\][:Z3J,EI#NGBTZ]D
M@?\ !_X<?\$Z_P!L+X=?!#]FE+RU_9H\1?'#]C3]C/PA^RS\'_"UMXW\7ZY\
M/O$7BC6?C7^SMX[^,7Q:N?'7C+X$Z<_@KQ1I/A3]G_PJOP*>/X9^,G\(?$)Y
MO%>IMJ,VEZ;!9_T%;5]/3N1T^AZ'N.A[YIAAB/5<].<MN^4L5PV=PV%B8\']
MVV&3:0" #^=;2/\ @E/^TC8_L_>+_A]::[\'-)\=>,_V)/VG?V4/$>@WOQ!\
M<:QX%\3^,;WXP?$_4/V4?BKJ'C*Y^%]YXL2V\*?"O]I+]H^T\=Z=?>$_$5__
M &CXOT+PZL^KM;'Q#I^CXQ_X)U_M-^)/'4OA_P 9_"W]G+XQ? ./XS_MJ^.?
M$=AK_P ;/B'X8\7>//AA^V:OP\U[7?"5DVA_"BUN=$^*7PUU6U\>^'/!/C)_
M%7AFR,'AWX<>+X?$7AK7Q>Z+8?T+K!"I)5!EMNXDL=VQ-B@[B<JJ\*I^4$E@
M Q)+6M;=BI,2_+C RP7C& 5!"D @'!!&Y4;&Y%( /PI\!_\ !-_]HWP]XO\
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0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
